干扰素与维拉帕米逆转乳腺癌细胞耐药作用的研究

目的:研究α-干扰素与维拉帕米对体外培养的乳腺癌细胞多药耐药(MDR)的逆转作用。方法:以对药物敏感的人乳腺癌细胞系MCF-7和经阿霉素(ADM)诱导具有MDR表型的人乳腺癌耐药细胞系MCF-7/ADR为体外试验模型,分别单用及联用α-干扰素与维拉帕米对细胞系进行处理,MTT法检测各组细胞存活率,计算半数抑制浓度(IC50)、耐药倍数和逆转倍数;流式细胞术定量检测细胞表面P-170的表达。结果:α-干扰素与维拉帕米联用后使乳腺癌细胞耐ADM的IC50降低为0.32μmol·L-1,优于二者单用(2.29、1.23μmol·L-1),逆转倍数升高到51.88(二者单用为7.25、13.49),P-170表达低于二者单用。结论:单独应用α-干扰素、维拉帕米均可达到部分逆转MCF-7/ADR对ADM的耐药作用,但二者联用效果更强。

Interferon and Verapamil for the Reversal of Multidrug Resistance in Breast Cancer Cell Line

OBJECTIVE： To investigate the effect of interferon-α and verapamil on the reversal of multidrug-resistance （MDR） in breast cancer cell line. METHODS： Drug- sensitive MCF-7 and ADM induced MDR phenotypic MCF-7/ADR were taken as in vitro experimental models, which were treated with interferon-α and verapamil in combination or alone, then the cell survival rate, IC50, drug- resistant times and reversal times of different experiment groups were measured by MTT test. The quantitive expression of P - 170 on the surface of cells was detected by flow cytometry. RESULTS： Treated by interferon-α and verapamil in combination, the IC50 of adriamycin- resistance was lowered to 0.32μmol·L^-1, superior to verapamil （1.23 μmol·L^-1） or interferon-α （2.29 μmol·L^-1） alone; the reversal times increased to 51.88 in combination group, superior to interferon-α and verapamil alone （7.25 and 13.49 respectively） and the expression of P - 170 were lower than in groups treated with interferon-α and verapamil alone. CONCLUSION： The efficacy of interferon-α and verapamil exhibited a more remarkable efficacy on the reversal of multidrug - resistance （MDR） in breast cancer cell line when used in combination than alone.